BUFFALO, NY--(Marketwire - October 27, 2008) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced results of a series of studies demonstrating Protectan CBLB612's ability to substantially reduce myelosuppression (the most common rate limiting adverse effect of chemotherapy) caused by a widely used chemotherapeutic drug, cyclophosphamide (Cytoxan, Neosar, CTX).
